Madiha Derouazi is the Founder and CEO of AMAL Therapeutics.

Madiha founded AMAL in 2012 as a spin-off from the University of Geneva, Switzerland, and focuses on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.

Madiha has been working on vector engineering and therapeutic cancer vaccines for over 15 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research, the so-called bench-to-bedside. She designed and characterized a CPP-based multi-epitopic cancer vaccine in the Laboratory of Tumour Immunology of the University of Geneva, which is the basis of the KISIMA platform.

Madiha holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany. She now continues to lead the AMAL team in Switzerland, and excitingly drives the integration into the Boehringer Ingelheim oncology research and development family.